<DOC>
	<DOCNO>NCT01535612</DOCNO>
	<brief_summary>The purpose study evaluate ability patient , type 2 diabetes ( T2DM ) currently treat basal/bolus insulin therapy , use PaQ™ ( simple patch insulin delivery device ) control his/her blood glucose .</brief_summary>
	<brief_title>Study PaQ™ ( Simple Patch Insulin Delivery Device ) Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This single center , open label , feasibility use performance evaluation PaQ™ ( use insulin aspart ) patient T2DM currently receive basal/bolus insulin therapy without oral anti-diabetic drug ( OADs ) glycemic control . The patient 's participation study comprise four phase : screening , baseline evaluation , transition PaQ™ use , PaQ™ treatment period . The use phase allow orderly transition PaQ™ treatment well reliable construct interpret final data .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Male/female patient 's ≥ 30 ≤ 65 year age . 2 . Clinical confirmation T2DM diagnosis history medication usage glucose tolerance test . 3 . Currently treat insulin use basal/bolus regimen without concurrent use OADs ( metformin and/or glitazone ) . 4 . Currently stable insulin regimen `` judge investigator '' ( use estimate basal dose insulin fluctuate ±10 % every day ) he/she receive concurrent oral agent , dose remain unchanged last 30 day . 5 . Currently use 20 50 units/day basal insulin . 1 . Uncontrolled hyperglycemia , HbA1c &gt; 9.0 % require adjustment his/her insulin regimen . 2 . Treated premixed insulin , neutral protamine hagedorn ( NPH ) /glargine/detemir insulin without use bolus/meal time insulin . 3 . Patient episode severe ( assist ) hypoglycemia within past 30 day . 4 . Currently treat sulfonylurea incretinbased therapy [ glucagonlike peptide1 ( GLP1 ) agonist dipeptidyl peptidase4 ( DPP4 ) inhibitor ] . 5 . Total daily dose ( TDD ) insulin &gt; 100 units/day . 6 . Have mealtime bolus dos exceed capacity bolus Insulin Reservoir give meal . 7 . Have exist dermal irritation abdomen know hypersensitivity skin adhesive . 8 . Taking take prednisone cortisone medication previous 30 day . 9 . Pregnant plan become pregnant study period . 10 . Has severe medical psychological condition ( ) chronic conditions/infections opinion Investigator would compromise patient 's safety successful participation study . 11 . Unable follow study clinical investigational plan ( CIP )</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>